FDA Approves First Non-Hodgkin's Lymphoma Biosimilar
The U.S. Food and Drug Administration on Wednesday approved Celltrion and Teva's version of the blockbuster cancer treatment Rituxan, marking the first biosimilar approved in the U.S. to treat non-Hodgkin's lymphoma....To view the full article, register now.
Already a subscriber? Click here to view full article